share_log

Ascendiant Capital Maintains Buy on Surgepays, Lowers Price Target to $9

Benzinga ·  Sep 11 18:00  · Ratings

Ascendiant Capital analyst Edward Woo maintains Surgepays (NASDAQ:SURG) with a Buy and lowers the price target from $9.5 to $9.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment